In vivo, 15 mg/kg ARav inhibited T1889 xenograft tumor growth more efficaciously than vehicle...Combining ARav at a dose of 7.5 mg/kg with 4 mg/kg cisplatin yielded an additive effect on inhibiting tumor growth.... Anetumab ravtansine inhibits growth of MSLN positive thymic carcinoma in our preclinical model; when combined with SoC cisplatin, ARav confers enhanced tumor growth inhibition.

In vivo, 15 mg/kg ARav inhibited T1889 xenograft tumor growth more efficaciously than vehicle...Combining ARav at a dose of 7.5 mg/kg with 4 mg/kg cisplatin yielded an additive effect on inhibiting tumor growth.... Anetumab ravtansine inhibits growth of MSLN positive thymic carcinoma in our preclinical model; when combined with SoC cisplatin, ARav confers enhanced tumor growth inhibition.

ARav’s activity in-vivo as a monotherapy, and as a combination therapy with cisplatin, was tested against MSLN expressing T1889 xenograft tumors...Anetumab ravtansine inhibits growth of MSLN positive thymic carcinoma in our preclinical model...

ARav’s activity in-vivo as a monotherapy, and as a combination therapy with cisplatin, was tested against MSLN expressing T1889 xenograft tumors...when combined with SoC cisplatin, ARav confers enhanced tumor growth inhibition.